Macorate CR 400 Tablet contains Magnesium Valproate 400 mg, an anticonvulsant and mood-stabilizing agent primarily used in the management of epilepsy and bipolar disorder. Magnesium Valproate acts by increasing the availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system, thereby stabilizing neuronal activity and preventing seizure propagation. This controlled-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency. Macorate CR 400 is indicated for the treatment of various types of seizures, including generalized tonic-clonic, absence, and complex partial seizures, as well as for the prophylaxis of migraine and the management of manic episodes associated with bipolar disorder. The medication should be used under strict medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, dizziness, weight gain, and tremors, while serious side effects such as hepatotoxicity and pancreatitis require immediate medical attention. Regular monitoring of liver function tests and blood counts is recommended during prolonged therapy. Macorate CR 400 Tablet should be avoided in patients with known hypersensitivity to valproate compounds, severe hepatic impairment, or urea cycle disorders. It is essential to inform healthcare providers of all concomitant medications to prevent potential drug interactions.